United Therapeutics Corp
UTHR: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$729.00 | Pnth | Gyqgkyz |
United Therapeutics Earnings: Demand for Tyvaso DPI Drives Strong Sales; Shares Fairly Valued
United Therapeutics reported strong third-quarter results highlighted by revenue of $609 million, representing growth of 18% year over year. Tyvaso DPI, a dry powder inhaler for the treatment of pulmonary arterial hypertension, or PAH, launched in June 2022 and has continued to see strong patient demand. We maintain our fair value estimate of $221 per share, and we view shares as fairly valued, currently trading in 3-star territory.